Matrix metalloproteinases plasma levels

Ebata, M., Fukuda, Y., Nakano, L, Katano, Y., Fujimoto, N., and Hayakawa, T., Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver 17, 293-299 (1997). Ebihara, L, Nakamura, T., Shimada, N., and Koide, H., Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am. J. Kidney Dis. 32, 544-550 (1998). 

H3. Hayasaka, A., Suzuki, N., Fujimoto, N., Iwama, S., Fukuyama, E., Kanda, Y., and Saisho, H., Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24, 1058-1062... 

Inokubo, Y., Hanada, H., Ishizaka, H., Fukushi, T., Kamada, T., and Okumura, K., Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metaUoproteinase-... 

L6. Lindholt, J. S., Vammen, S., Fasting, H., Henneberg, E. W., and Heickendorff, L., The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur. J. Vase. Endovasc. Surg. 20, 281-285 (2000). 

L8. Lizasa, T., Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin. Cancer. Res. 5, 149-153 (1999). 

LIO. Lorenzl, S., Albers, D. S., Relkin, N., et at. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer s disease. Neurochem. Int. 43, 191-196 (2003). 

M2. Manenti, L., Paganetti, P. A., Floriani, L, et at. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur. 

Susskind, H., Hymowitz, M. H., Lau, Y. H., et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int. J. Radiat. Oncol. Biol. Pkys. 56, 1161-1169 (2003). 

V6. Vuoristo, M. S., Kellokumpu-Lehtinen, P., Parvinen, L. M., Hahka-Kemppinen, M., Korpela, M., Kumpulainen, E., and Laine, S., Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol. 39, 877-879 (2000). Walsh, K. M., Timms, P., Campbell, S., MacSween, R. N., and Morris, A. J., Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloprotei-nases-1 and-2 (TlMP-1 and TlMP-2) as noninvasive markers of hver disease in chronic hepatitis C Comparison using ROC analysis. Dig. Dis. Sci. 44, 624-630 (1999). 

The results indicated that lycopene could effectively suppress the growth and progression of colon cancer in tumor-bearing mice. They also demonstrated that lycopene significantly suppressed the nuclear expression of PCNA and p-catenin proteins in tumor tissues. Consumption of lycopene could also augment the E-cadherin adherent molecule and nuclear levels of cell cycle inhibitor p21(CIPlAVAFl) protein. The chemopreventive effects of lycopene were associated with suppression of COX-2, PGE(2), and phosphorylated ERKl/2 proteins. Furthermore, the inhibitory effects of lycopene were inversely correlated with the plasma levels of matrix metalloproteinase 9 (MMP-9) in tumor-bearing mice. 

---